TrialThe Journal of infectious diseases2026
Serum Virus-Neutralizing Antibody Titers in Clinical Trial Participants With and Without Immunocompromise Receiving Pemivibart, a Long-Acting Monoclonal Antibody for COVID-19.
Kristin Narayan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.